Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Boston Scientific's Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN75,035 Mil. Therefore, Boston Scientific's EV-to-EBIT ratio for today is 17.38.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Boston Scientific's Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN100,537 Mil. Therefore, Boston Scientific's EV-to-EBITDA ratio for today is 12.97.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Boston Scientific's Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN377,210 Mil. Therefore, Boston Scientific's EV-to-Revenue ratio for today is 3.46.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Boston Scientific's Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN60,660 Mil. Therefore, Boston Scientific's EV-to-FCF ratio for today is 21.50.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Boston Scientific (MEX:BSX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN75,035 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN100,537 Mil.
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN377,210 Mil.
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN79,686 Mil.
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil.
Boston Scientific's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN60,660 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific Enterprise Value Related Terms
Boston Scientific Enterprise Value Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BSX vs EW, GEHC, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Boston Scientific's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Boston Scientific's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN1,304,108 Mil mean?
Boston Scientific (MEX:BSX) has a Enterprise Value of MXN1,304,108 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Enterprise Value too high?
Boston Scientific's current Enterprise Value is MXN1,304,108 Mil. Overall, Boston Scientific has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Enterprise Value compare to EW and GEHC?
Boston Scientific's Enterprise Value of MXN1,304,108 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Boston Scientific and its competitors. Boston Scientific's current Enterprise Value is MXN1,304,108 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,840.77, compared to a current price of MXN759.00 — trading 58.8% below its estimated fair value. The current Enterprise Value is MXN1,304,108 Mil. Boston Scientific's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current Enterprise Value is MXN1,304,108 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (MEX:BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of MXN759.00 is trading 58.8% below its estimated GF Value™ of MXN1,840.77.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for MEX:BSX:
Enterprise Value: MXN1,304,108 Mil
GF Value™: MXN1,840.77 vs. price of MXN759.00 (58.8% below fair value)
No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
83GF Score
Get the complete analysis for MEX:BSX
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BSX has been successfully added to your 
